14例斯鲁利单抗治疗小细胞肺癌所致免疫相关不良事件病例分析

doi:10.3969/j.issn.2095-1264.2025.03.12

首页 > 过刊浏览>2025年第15卷第3期 >378-384. DOI:10.3969/j.issn.2095-1264.2025.03.12

14例斯鲁利单抗治疗小细胞肺癌所致免疫相关不良事件病例分析
DOI:
                        10.3969/j.issn.2095-1264.2025.03.12
                    
CSTR:
                        
                    
作者:
                        
                        
                    
作者单位:1.怀化市中心医院/怀化市肿瘤医院，湖南 怀化，418000;2.湖南省肿瘤医院，湖南 长沙，410013
作者简介:申超赞，男，副主任药师，研究方向为抗肿瘤临床药学。
通讯作者:罗佳，女，硕士，主任药师，研究方向为抗肿瘤临床药学。
中图分类号:R735.2
基金项目:

Analysis of 14 cases of immune-related adverse events induced by serplulimab treatment for small cell lung cancer

Author:

Affiliation:

1.Huaihua Central Hospital/Huaihua Cancer Hospital, Huaihua, 418000, Hunan, China;2.Hunan Cancer Hospital, Changsha, 410013, Hunan, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

目的探讨斯鲁利单抗治疗小细胞肺癌（SCLC）所致免疫相关不良事件（irAE）的临床表现及特点。方法收集湖南省肿瘤医院、怀化市中心医院（怀化市肿瘤医院）2022年1月至2023年12月使用斯鲁利单抗治疗SCLC后导致irAEs的病例资料，进行回顾性分析。结果共收集到14例irAEs病例，其中男性11例（78.57%），女性3例（21.43%）；平均年龄为58.93岁；9例（64.29%）有吸烟史或饮酒史；11例（78.57%）合并基础疾病；3例（21.43%）联合化疗后采用斯鲁利单抗单药维持治疗，11例（78.57%）采用联合化疗。irAEs中位发生时间为76 d，主要临床表现为免疫性甲状腺功能减退、免疫性心肌炎、免疫性肺炎等，其中4例（28.57%）合并其他irAEs。14例患者经治疗后有12例（85.71%）好转/稍好转，1例（7.14%）未好转，1例（7.14%）转归未知。结论斯鲁利单抗与其他PD-1抑制剂类似，可引起多种irAEs，临床应用时应加强irAEs管理，保障安全用药。

Abstract:

Objective To investigate the clinical manifestations and characteristics of immune-related adverse events (irAEs) induced by serplulimab in small cell lung cancer (SCLC) patients.Methods The clinical data of SCLC patients with irAEs induced by serplulimab in Hunan Cancer Hospital and Huaihua Central Hospital (Huaihua Cancer Hospital) from January 2022 to December 2023 were collected and retrospectively analyzed.Results A total of 14 cases of irAEs were collected, including 11 males (78.57%) and 3 females (21.43%). The mean age was 58.93 years. 9 patients (64.29%) had smoking/alcohol history. 11 patients (78.57%) presented comorbidities. 11 (78.57%) were treated with combined chemotherapy and 3 (21.43%) were treated with serplulimab monotherapy after combined chemotherapy. The median irAEs onset was 76 days, with primary manifestations being immune-mediated hypothyroidism, myocarditis, and pneumonitis. Among them, 4 patients (28.57%) were complicated with other irAEs. Clinical outcomes showed that 12 patients (85.71%) achieved improvement/partial improvement, 1 patient (7.14%) had no improvement, and 1 patient (7.14%) were lost to follow-up.Conclusion Serplulimab, similar to other PD-1 inhibitors, can cause a variety of irAEs requiring enhanced monitoring protocols to ensure treatment safety in clinical practice.